Abstract:Runan Zuo, 1 Yan Zhang, 1 Xiaorong Chen, 1 Shiheng Hu, 1 Xinhao Song, 1 Xiuge Gao, 1 Jiahao Gong, 1 Hui Ji, 1 Fengzhu Yang, 1 Lin Peng, 1 Kun Fang, 2 Yingjun Lv, 1 Junren Zhang, 1 Shanxiang Jiang, 1 Dawei Guo 1 1 Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China; 2 The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, People's Republic of China Correspondence: Dawei Guo; Shanxiang Jiang, Engineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, MOE Joint International Research Laboratory of Animal, Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, People's Republic of China, Tel +86 25-84396215, Fax +86-25-84398669, Email ; Background: Halofuginone (HF)-loaded TPGS polymeric micelles (HTPM) were successfully fabricated using the thin-film hydration technique. HTPM via intravenous injection have been demonstrated to exert an excellent anticancer effect against triple-negative breast cancer (TNBC) cells and subcutaneous xenografts. In the present study, we further explored the potential treatment effect and mechanism of orally administered HTPM alone and in combination with surgical therapy on TNBC in subcutaneous and orthotopic mouse models. Methods: Herein, the stability and in vitro release behavior of HTPM were first evaluated in the simulated gastrointestinal fluids. Caco-2 cell monolayers were then used to investigate the absorption and transport patterns of HF with/without encapsulation in TPGS polymeric micelles. Subsequently, the therapeutic effect of orally administered HTPM was checked on subcutaneous xenografts of TNBC in nude mice. Ultimately, orally administered HTPM, combined with surgical therapy, were utilized to treat orthotopic TNBC in nude mice. Results: Our data confirmed that HTPM exhibited good stability and sustained release in the simulated gastrointestinal fluids. HF was authenticated to be a substrate of P-glycoprotein (P-gp), and its permeability across Caco-2 cell monolayers was markedly enhanced via heightening intracellular absorption and inhibiting P-gp efflux due to encapsulation in TPGS polymeric micelles. Compared with HF alone, HTPM showed stronger tumor-suppressing effects in subcutaneous xenografts of MDA-MB-231 cells when orally administered. Moreover, compared with HTPM or surgical therapy alone, peroral HTPM combined with partial surgical excision synergistically retarded the growth of orthotopic TNBC. Fundamentally, HTPM orally administered at the therapeutic dose did not cause any pathological injury, while HF alone led to weight loss and jejunal bleeding in the investigated mice. Conclusion: Taken together, HTPM could be applied as a potential anticancer agent for TNBC by oral administration. Graphical Keywords: triple-negative breast cancer, Halofuginone hydrobromide, TPGS polymeric micelles, subcutaneous xenografts, orthotopic xenografts, oral administration Graphical Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer that accounts for 10–20% of all invasive breast cancers. 1 TNBC is characterized by its more invasive nature, greater recurrence and metastasis potentials, and poorer outcomes compared with other major subtypes of breast cancer. 2,3 TNBC is not sensitive to endocrine therapy or HER-2–targeted treatment due to the absence or minimal expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) in TNBC cells. 4,5 Current treatment options for patients with TNBC include a combination of surgery, radiotherapy, and/or systemic chemotherapy. While chemotherapy remains the standard treatment for TNBC, 6 resistance to chemotherapy frequently develops, which results in a high mortality rate. Therefore, there is an urgent clinical need to develop novel therapeutic strategies for TNBC to improve survival rates in this patient population. Halofuginone hydrobromide (HF) is a synthetic analogue of febrifugine derived from the Chinese herb Dichroa febrifuga . 7 It has been used to prevent coccidiosis in poultry and treat human scleroderma, as approved by the US Food and Drug Administration -Abstract Truncated-

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis

Halofuginone inhibits the establishment and progression of melanoma bone metastases

Halofuginone prevents estrogen-deficient osteoporosis in mice.

Halofuginone Inhibits Osteoclastogenesis and Enhances Osteoblastogenesis by Regulating Th17/Treg Cell Balance in Multiple Myeloma Mice with Bone Lesions

Inhibition of TGF-&beta; Signaling with Halofuginone Can Enhance the Antitumor Effect of Irradiation in Lewis Lung Cancer

Halofuginone Attenuates Osteoarthritis by Inhibition of TGF-β Activity and H-type Vessel Formation in Subchondral Bone

New Uses of Halofuginone to Treat Cancer

Halofuginone Inhibits Colorectal Cancer Growth Through Suppression of Akt/mTORC1 Signaling and Glucose Metabolism

Zoledronic Acid Sensitizes Breast Cancer Cells to Fulvestrant Via ERK/HIF-1 Pathway Inhibition Inï¿½vivo

Orally Administered Halofuginone-Loaded TPGS Polymeric Micelles Against Triple-Negative Breast Cancer: Enhanced Absorption and Efficacy with Reduced Toxicity and Metastasis

Halofuginone inhibits tumor migration and invasion by affecting cancer-associated fibroblasts in oral squamous cell carcinoma

New Insights into the Actions of Bisphosphonate Zoledronic Acid in Breast Cancer Cells by Dual RhoA-dependent and -Independent Effects

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

Study of Halofuginone in Ameliorating Radiation Injury of Lung

Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models

Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment

Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation

Effect of Halofuginone on the Inhibition of Proliferation and Invasion of Hepatocellular Carcinoma HepG2 Cell Line.

Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction

Dual Targeted Zeolitic Imidazolate Framework Nanoparticles for Treating Metastatic Breast Cancer and Inhibiting Bone Destruction.